Of note, the results of our in vitro and in vivo experiments demonstrate that CD44, which was highly expressed in SCLC-non-NE populations, which are present to some degree in nearly all SCLC tumors, may be targeted to enhance the treatment efficacy of chemotherapy (cisplatin plus etoposide) for SCLC. The gene discussed is CD44; the disease is small cell lung carcinoma.